Sort   by:  
 Page size 
ProteomicsSpatial SILAC Regorafenib Treated Bottom-up Proteomic Analysis
Developing effective model systems to evaluate new potential chemotherapeutic reagents is critical. Three-dimensional cell cultures, such as spheroids, aid in bridging the gap between commonly used monolayer cell cultures and significantly more complex and expensive animal models. Spheroid model sys...
ORGANISM(S): Homo sapiens (Human) 
2024-08-09 | PXD038958 | Pride
Spatial silac Regorafenib Spheroids 
GenomicsRole of regorafenib in macrophage
Role of regorafenib in macrophage
PRJNA626614 | ENA
GenomicsExpression data from cholangiocarcinoma cell lines and regorafenib treatment.
Expression data from cholangiocarcinoma cell lines and regorafenib treatment.
PRJNA627437 | ENA
GenomicsRole of regorafenib in antitumor immunity in hepatocellular carcinoma
Role of regorafenib in antitumor immunity in hepatocellular carcinoma
PRJNA626615 | ENA
GenomicsCombination of dual JAK/HDAC inhibitor with regorafenib reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
Combination of dual JAK/HDAC inhibitor with regorafenib reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer
PRJNA1061163 | ENA
GenomicsRNA-Seq analysis of the effect of regorafenib on melanoma cells
RNA-Seq analysis of the effect of regorafenib on melanoma cells
PRJNA1143462 | ENA
TranscriptomicsRole of regorafenib in macrophage
Regorafenib increased M1/M2 ratio of BMDMs polarization and proliferation/activation of co-cultured T cells in vitro, indicating angiogenesis-independent immunomodulatory effects. Suppression of p38 kinase phosphorylation and downstream CREB-KLF4 activity in BMDMs by regorafenib reversed M2 polariza...
ORGANISM(S): Mus musculus 
2021-01-27 | GSE148948 | GEO
GenomicsSpatial transcriptomics data of GAN-KP tumor treated with regorafenib
Spatial transcriptomics data of GAN-KP tumor treated with regorafenib
PRJNA885067 | ENA
GenomicsProteoglycan 4 and regorafenib synergistically reduce HCC progression in an orthotopic model
Proteoglycan 4 and regorafenib synergistically reduce HCC progression in an orthotopic model
PRJNA1277109 | ENA
TranscriptomicsRole of regorafenib in antitumor immunity in hepatocellular carcinoma
Low-dose regorafenib (5 mg/kg/day, corresponding to about half of human clinical dosage) inhibited tumor growth and angiogenesis in vivo similarly to DC-101 (anti-VEGFR antibody) but produced higher T cell activation and M1 macrophage polarization, Regorafenib increased M1/M2 ratio of BMDMs polariza...
ORGANISM(S): Mus musculus 
2021-01-27 | GSE148947 | GEO
Sort   by:  
 Page size